IJIn Hyun Jung

In Hyun Jung

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


In Hyun Jung has a total of 148 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prediction of left ventricular systolic dysfunction from chest radiographs using validated abnormality labels plus machine learning versus end-to-end deep learning

    by SungA Bae, Yujee Chang, Jinsik Yoon, Minkwan Kim, Hyun Joo Shin, Eun-Kyung Kim, Ju Gang Nam, Chang Min Park, Dukyong Yoon, In Hyun Jung

  • Open Access

    Comparative Risk of Incident Gout Across Angiotensin Receptor Blockers in Amlodipine-Based Combination Therapy: A Nationwide Target Trial Emulation Study

    by In Tae Jin, So Jeong Park, Yujin Lee, SungA Bae, In Hyun Jung

    Background: Losartan is the only commonly used angiotensin receptor blocker (ARB) with a recognized uricosuric effect, but whether the choice of ARB within amlodipine-based combination therapy is associated with differences in incident gout risk remains uncertain. Methods: We emulated a target trial using the Korean National Health Insurance Service database with a new-user, active-comparator design. Adults aged 20 years or older with newly diagnosed hypertension who initiated amlodipine/ARB combination therapy (losartan, olmesartan, telmisartan, or valsartan) between 2010 and 2013 were included (n=128,779). The primary outcome was new-onset gout; secondary outcomes were gout-related emergency department visits and major adverse cardiovascular events (MACE). Hazard ratios (HRs) were estimated using inverse probability of treatment weighting-adjusted Cox proportional hazards models with robust standard errors. Findings: Among 98,356 persistent users (amlodipine/losartan, n=35,588; amlodipine/olmesartan, n=14,294; amlodipine/telmisartan, n=25,441; amlodipine/valsartan, n=23,033), the risk of new-onset gout was higher for amlodipine/olmesartan (HR, 1·22 [95% CI, 1·13–1·31]), amlodipine/telmisartan (HR, 1·15 [95% CI, 1·08–1·23]), and amlodipine/valsartan (HR, 1·13 [95% CI, 1·06–1·21]) compared with amlodipine/losartan. Risks of gout-related emergency department visits and MACE did not differ significantly across groups, and findings were consistent across medication adherence strata and prespecified subgroups. Interpretation: Among adults with newly diagnosed hypertension receiving amlodipine-based combination therapy, incident gout risk differed according to the ARB component, with the most favorable association observed for losartan and no apparent tradeoff in cardiovascular outcomes. These findings support consideration of losartan-containing combination therapy when gout risk is a clinical concern.

  • Open Access

    Effectiveness of low-dose SGLT2 inhibitors in diabetic patients with heart failure: a nationwide cohort study

    by Minkwan Kim, Seok-Jae Heo, SungA Bae, In Hyun Jung, Deok-Kyu Cho

    Background and objectives: SGLT2 inhibitors (SGLT2i) are a cornerstone of guideline-directed therapy for heart failure (HF). However, the optimal dose for HF remains unclear, as no phase II trials have evaluated dose-response in this population. This study aimed to evaluate whether low-dose (5 mg) of SGLT2i provide comparable efficacy and safety compared with the standard 10 mg dose and to non-users. Methods: This nationwide retrospective cohort study utilized Korean National Health Insurance Service claims data (2013–2018), including 551,760 patients with HF and diabetes, of whom 55,694 were SGLT2i users. After exclusions, propensity-score matching was performed in a 5:5:1 ratio (non-users:10 mg:5 mg). The composite primary outcome was cardiac death, HF hospitalization, or urgent HF-related emergency department (ED) visit. Safety outcomes included ketoacidosis, acute kidney injury (AKI), urinary tract infection, and fractures. Results: In the matched cohort (2,637 on 5 mg; 13,185 on 10 mg; 13,185 non-users), the 5 mg group was associated with lower risk of the primary outcome (HR: 0.73, 95% CI: 0.66–0.81; P < 0.001) and all-cause death (HR 0.85, 95% CI 0.74–0.97; P = 0.019) compared with 10 mg, with similar safety profiles. Significant interactions were observed: the relative effect of 5 mg vs. 10 mg differed by sex and body weight for urgent ED visits, and by BMI for AKI. Sensitivity analyses across multiple time points showed consistent results, with the 5 mg group associated with comparable or lower risk compared with the 10 mg group. Conclusions: In patients with diabetes and HF, 5 mg daily SGLT2i was associated with a comparable risk to 10 mg, warranting randomized dose-finding trials.

  • Open Access

    Evaluation of guideline adherence to hypertension-mediated organ damage screening in Korean patients with hypertension: results from the Korean Registry of Target Organ Damage in Hypertension (KorHR)

    by Do Young Kim, Sung Hea Kim, Seong Woo Han, Jong Sun Ok, Jung-Woo Son, Jin-Ok Jeong, Eung Ju Kim, Seonghoon Choi, In Hyun Jung, Sung Kee Ryu, et al.

    Kim DY, et al. Clin Hypertens. 2026 ;32(1):e11. https://doi.org/10.5646/ch.2026.32.e11


  • Open Access

    Clinical Usefulness of Left Ventricular Global Longitudinal Strain as a Predictor of Prognosis in Patients With Acute Ischemic Stroke (GLS‐STROKE Study)

    by Minkwan Kim, Joonsang Yoo, Minyoul Baik, Jinkwon Kim, In Hyun Jung

    Background: The prognostic role of left ventricular global longitudinal strain (LV‐GLS) in acute ischemic stroke (AIS) remains unexplored despite its established value in cardiovascular conditions. We aimed to investigate the prognostic value of LV‐GLS in patients with AIS. Methods: In this prospective cohort study, 698 patients with AIS (mean age, 67.6±13.8 years; 60.2% men) underwent transthoracic echocardiography using speckle‐tracking to measure LV‐GLS within 7 days of admission. The primary end points included all‐cause death and recurrent ischemic stroke, with a 3‐month modified Rankin Scale score ≥3 considered a poor outcome. Results: Over a median follow‐up of 593 days, the primary end point occurred in 65 patients (9.3%), with significant differences in LV‐GLS between those reaching the end point (16.3%) and the others (19.1%; P P 2 and continuous net reclassification index analyses (0.25 [95% CI, 0.01–0.42]; P =0.044). Subgroup analysis revealed the prognostic relevance of LV‐GLS irrespective of atrial fibrillation status. In predicting a poor functional outcome, LV‐GLS also provided incremental value over traditional risk factors and the initial National Institutes of Health Stroke Scale score (continuous net reclassification index, 0.27 [95% CI, 0.09–0.45]; P =0.004). Conclusions: LV‐GLS is a robust predictor of cardiocerebrovascular outcomes in AIS and offers incremental prognostic value beyond traditional risk factors. Incorporating LV‐GLS into AIS management may help identify high‐risk patients and guide intensive monitoring strategies. Registration: URL: https://trialsearch.who.int . Unique identifier: KCT0005780.


  • Open Access

    Left atrial reservoir strain as a predictor for left ventricular filling pressure in patients with sinus rhythm

    by Minkwan Kim, Ji Woong Roh, Nak-Hoon Son, SungA Bae, Oh-Hyun Lee, In Hyun Jung, Deok-Kyu Cho

    We aimed to evaluate the utility of left atrial reservoir strain (LASr) as a predictor of left ventricular (LV) filling pressure measured via catheterization in patients with sinus rhythm. This prospective study collected data including pre-atrial contraction (pre-A) pressure and LV end-diastolic pressure (LVEDP) from patients undergoing LV catheterization. Transthoracic echocardiography was performed within 24 h to assess LA strain. Patients with supraventricular tachycardia or acute coronary syndrome were excluded. From June 2021 to September 2022, 365 patients (mean age 61.7 ± 11.5 years, 25.5% female) were enrolled. Mean LASr was 28.7 ± 7.4%. LASr demonstrated good discrimination for predicting LV pre-A pressure ≥ 15 mmHg (0.754, 95% CI 0.641–0.820), being significantly better than that of LVEDP ≥ 16 mmHg (0.655, 95% CI 0.592–0.719) using a 24% cutoff (p = 0.021). Adding LASr to a model based on HFA-PEFF components improved diagnostic performance (continuous net reclassification index 0.404, 95% CI 0.037–0.807, p = 0.032). In patients with indeterminate diastolic function, LASr ≥ 24% reclassified them as normal with 76.9% accuracy. When the 198 patients within the intermediate score group with LASr > 24% were reclassified as ‘HFpEF unlikely,’ 192 (97.0%) showed normal LV filling pressure. LASr is an independent predictor of LV filling pressure, especially LV pre-A pressure.


  • Impact of Emergency Medical Services Call–to–Hospital Arrival Time on Outcomes of Cardiac Arrest: A Nationwide Prospective Cohort

    by Oh-Hyun Lee, Seok-Jae Heo, SungA Bae, Moon-Hyun Kim, Je-Wook Park, Minkwan Kim, Ji Woong Roh, Eui Im, In Hyun Jung, Deok-Kyu Cho, et al.


  • Open Access

    Risk factors associated with SGLT2 inhibitor discontinuation in diabetic patients with heart failure

    by Minkwan Kim, Seok-Jae Heo, Moon-Hyun Kim, Je-Wook Park, SungA Bae, Ji Woong Roh, Oh-Hyun Lee, Yongcheol Kim, Eui Im, In Hyun Jung, et al.

    Sodium-glucose cotransporter 2 inhibitors (SGLT2i), have shown benefits in patient with heart failure (HF), however, adherence remains a significant issue: with only 60% of patients continuing usage beyond a year. This study aims to identify patients at risk of discontinuing SGLT2i and promote its judicious use to reduce hospitalizations and improve cardiovascular outcomes. Using the Korean National Health Insurance Service database, patients diagnosed with HF and diabetes mellitus (n = 1,665,565) between 2013 and 2018 were identified. Among them, 55,694 participants prescribed SGLT2i were enrolled. The primary endpoint included 1) all-cause mortality and 2) SGLT2i-related hospitalization, encompassing incidents such as ketoacidosis, acute kidney injury, urinary tract infections, fall-related fractures, and other unplanned hospitalizations. During the follow-up period (median: 2.3 years; range: 1.2–3.6 years), 8,463 participants reached the primary endpoint (25.5 for all-cause death and 39.4 for SGLT2i-related hospitalizations per 1,000 person-years). Independent risk factors for the primary endpoint in multivariate Cox regression and propensity-score matching analyses included age of ≥ 70 years, body mass index (BMI) 2, body weight pp<0.001). Old age, low weight or BMI, and the use of diuretics are risk factors that hinder the continuous use of SGLT2i in diabetic patients with HF. Close monitoring for side effects is essential when prescribing SGLT2i, particularly for those with multiple risk factors.